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ABSTRACT
The Eosinophilic Granulomatosis with Polyangiitis (formerly Churg- Strauss 
Syndrome) (EGPA) is a systemic inflammatory disease characterized by 
the presence of rhinitis, asthma, peripheral eosinophilia, and vasculitis—the 
latter being characteristic of the late stage of the disease. After several years 
from the onset of the disease, small- and medium-sized vessel vasculitis 
ensues, undertaking various organs and systems. Upper and lower airways, 
skin, nervous system, gastrointestinal tract, heart, and kidneys are the most 
commonly involved organs. It is believed that tissue injury is the result of 
processes mediated by antineutrophil cytoplasmic antibody (ANCA), or toxic 
mediators released by eosinophils. Although it is classified as ANCA-associated 
vasculitis, these autoantibodies are present in only 40% of cases. The authors 
report the case of a patient with EGPA, who had a history of asthma, peripheral 
and central neuropathy, palpable purpura, gastrointestinal micro perforation, 
peripheral eosinophilia, and the presence of myeloperoxidase-antineutrophil 
cytoplasmic antibody. Inflammatory parameters improved after the initiation 
of treatment, but 1 month after hospital discharge the patient developed 
symptoms compatible with pulmonary embolism and died. Thrombophilia that 
occurs in EGPA is due to the interaction between the inflammatory response 
and eosinophilia with the clotting system resulting in a pro-thrombotic state. 
Although not yet well-determined, the authors call attention to the possibility of 
the impact of thromboembolic events on the prognosis of patients with EGPA. 
In addition to the adequate immunosuppressive treatment, prophylaxis and 
treatment for thrombosis should never be overlooked.
Keywords: Churg–Strauss Syndrome; Granulomatous Allergic Angiitis; Anti-Neutrophil Cytoplasmic 
Antibody-Associated Vasculitis; Asthma; Pulmonary Embolism; Autopsy.
CASE REPORT
A 66-year-old female patient sought medical 
care complaining of pain and numbness in the 
extremities for 1 month, which progressed to lower 
limb weakness preventing her from walking. Her 
family also referred some episodes of mental 
confusion. Initial laboratory workup included total 
blood cell count, which showed normal erythrocyte 
and platelet counts, but leukocytosis (white blood 
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prescribed a single dose of ivermectin before daily 
prednisone 60 mg, followed by ceftriaxone because 
of a suspected infection. The laboratory workup is 
shown in Table 1.
The anti-neutrophil cytoplasmic antibody 
ANCA (ELISA) was positive to myeloperoxidase 
(MPO) and negative to PR3. ANA was positive until 
titration of 1/160 showing a nuclear centromeric 
pattern, and complement fractions C3 and C4 
were normal. Serology for hepatitis B, hepatitis 
C, and syphilis were negative. Cerebrospinal fluid 
examination revealed a colorless sample with 1 
leukocyte and 26 red blood cells, protein of 28.8 
mg/dL (RV: 30-40 mg/dL), glucose of 61 mg/
dL (concomitantly with normal glycemia), and a 
negative Pandy reaction. The culture of blood 
samples, urine, and cerebrospinal fluid (CSF) were 
negative for bacterial growth. The urinalysis showed 
proteinuria; occult blood, leukocyturia; 173.000/
mL, hematuria 278.000/mL, but no cylindruria. 
The electrocardiogram (ECG) showed sinus 
tachycardia. Doppler echocardiography evidenced 
a thickened aortic valve with slight insufficiency. 
The paranasal sinuses computed tomography 
(CT) showed involvement of the left frontal, right 
sphenoid, and bilateral ethmoid sinuses. The chest 
CT showed tenuous mosaic attenuation of the 
lung parenchyma more pronounced in the bases; 
the presence of non-calcified nodules scattered 
bilaterally ranging in size between 5 and 10 mm; 
and a hiatal hernia. The abdominal CT disclosed the 
presence of pneumoperitoneum of unknown origin.
The patient persisted with the complaint 
of epigastric abdominal pain but no signs of 
distension or peritoneal irritation were observed. 
The gastrointestinal transit was normal. The upper 
endoscopy revealed the presence of esophageal 
cell count = 21.200/mm3 (reference value [RV]: 
5,000–10,000 leukocytes/mm3) with marked 
eosinophilia (28% of eosinophils, RV: < 5%). 
Serum determination of glucose, TSH, free T4 and 
vitamin B12 were normal. Serology for HIV, HTLV 
I and HTLVII were negative. The chest x-ray was 
normal. The lumbar spine computed tomography 
(CT) showed degenerative changes. The 
electroneuromyography (EMG) showed subacute 
peripheral neuropathic process with motor and 
sensory impairment: severe distal axonal sensory 
impairment was predominant in upper and lower 
limbs; and severe proximal, middle, and distal 
axonal motor involvement in the left upper limb and 
was more pronounced in the lower limbs and right 
upper limb.
During ambulatory diagnostic investigation, 
the patient came to the emergency service 
complaining of diffuse abdominal pain with 
nausea and vomiting associated with skin lesions 
that appeared on her hands and feet. Physical 
examination showed an ill-looking patient, presenting 
mental confusion (coma Glasgow scale = 14) with 
blood pressure of 167/100 mmHg, a pulse rate of 
120 beats per minute (bpm), and room air oximetry 
of 99%. Thoracic and abdominal examinations were 
unremarkable. Muscle strength was grade III/IV in 
the upper limbs (predominantly distal), and grade 
I in the lower limbs. The skin showed the presence 
of livedo reticularis over the trunk and palpable 
purpura on the tips of the toes and hands. Slight 
lower limb edema was present. Medical past history 
included hypertension, asthma, and allergic rhinitis 
regularly medicated. With these clinical features, 
the diagnosis of systemic vasculitis, most probably 
Eosinophilic Granulomatosis with Polyangiitis 
(formerly Churg- Strauss Syndrome) (EGPA) was 
considered, and the patient was hospitalized and 
Table 1 – Laboratory workup
Exam Result RV Exam Result RV
Hemoglobin 10.1 12.3-15.3 g/dL Potassium 4.7 3.5-5.0 mEq/L
Hematocrit 30.7 36.0-45.0% AST 138 10-31 U/L
Leukocytes 27.8 4.4-11.3 × 10³/mm3 ALT 144 9-36 U/L
Eosinophil 52% 1-4% CK 1398 26-140 U/L
Platelet 593 150-400 × 10³/mm3 LDH 366 120-246 U/L
Creatinine 0.6 0.4-1.3 mg/dL TP 6.0 6.0-8.0 g/dL
Urea 34 10-50 mg/dL Albumin 2.8 3.0-5.0 g/dL
Sodium 131 136-146 mEq/L CRP 191 <5.0 mg/dL
ALT = alanine aminotransferase; AST = aspartate aminotransferase; CK = creatine phosphokinase, CRP = C-reactive protein; LDH = lactic 
dehydrogenase; RV = reference value; TP = total protein.
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anemia (hemoglobin = 11.6 g/dL, RV: 13-15 g/dL). 
The remaining blood cell count, renal function, 
electrolytes, hepatic enzymes, CRP, CK, CK-MB and 
troponin I were all normal. The electrocardiogram 
showed a recent right bundle branch blockage. The 
acute clinical failure was interpreted as a pulmonary 
embolism. An autopsy was performed.
AUTOPSY
Resolving hemorrhagic skin lesions were 
seen on the hands and feet. At microscopic 
examination the lesions were in a chronic phase, 
with less fibrin deposition and more fibrosis and 
vascular occlusion (Figure 1).
Bilateral pulmonary thromboembolism 
was detected at gross examination (Figure 2). 
Right cardiac chambers were enlarged, which 
was consistent with acute cor pulmonale. A right 
pleural effusion was present and, at microscopic 
examination, the lungs showed alveolar hemorrhage, 
congestion, and edema. Small airways showed mild 
inflammation and basal membrane thickening, which 
was interpreted as treated asthma. Some subpleural 
small nodules had a dense fibrotic pigmented 
lesion which was consistent with silicoanthracosis 
(autopsy finding).
Active vasculitis with arteriolar wall necrosis, 
a palisade of histiocytes and inflammatory infiltrate 
with eosinophils and fibrin thrombi was present in 
skeletal muscle and at the periphery of nerves.
moniliasis and multiple acute superficial gastric 
ulcers, the biopsy of which revealed a chronic 
gastric ulcer edge in pyloric mucosa, Helicobacter 
pylori negative. These findings were interpreted 
as compatible with a tamponade gastric micro 
perforation. Because of steady clinical appearance, 
a proton-pump inhibitor was chosen instead of the 
surgical approach. Skin biopsy of the palmar injury 
showed sub epidermal necrosis with fibrin and 
erythrocytes. Neutrophilic vasculitis was depicted, 
showing vessel wall necrosis with red blood cell 
leakage permeated by eosinophils.
After the initiation of corticosteroid therapy, 
an improvement in mental status was observed 
as well as a decrease in the eosinophils count, 
creatine phosphokinase, and C-reactive protein 
determinations, and also a slight improvement 
in muscle strength. With the diagnosis of EGPA, 
the patient was referred to a specialized clinic for 
supplementary immunosuppressive therapy.
One month after the hospital discharge, she 
returned complaining of generalized pain and a 
burning sensation throughout the body. She denied 
fever, chest pain, breathlessness, or headache. 
On examination she was pale. Blood pressure 
was 130/82 mmHg, pulse rate of 92 bpm, room air 
oximetry of 92%. Neurological examination revealed 
a distal symmetrical weakness (members distal 
muscle strength grade I and proximal grade III). 
The presence of scarring necrotic lesions on toes 
was noted. Four hours after admission, the patient 
presented sudden dyspnea, mental confusion, 
worsening of muscular weakness, pallor, and 
cold sweating, progressing to cardiac arrest and 
death. Recent laboratory workup showed a mild 
Figure 1 – A - Spotty resolving skin purpuric lesions; B - Photomicrography of the skin biopsy taken at the 
acute phase of the disease showing leukocytoclastic vasculitis (H&E 200x).
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crateriform necrotic ulcers and mural vascular 
lesions in a chronic healing phase (Figure 4). 
The kidneys were small and granular and 
at microscopy revealed moderate nephrosclerosis 
related to active and chronic eosinophilic and 
necrotic vasculitis with a palisade of histiocytes. 
Acute glomerulonephritis was not detected. Healing 
The gastrointestinal tract was particularly 
affected by active vasculitis. Inflammation of small 
arteries was detected in the wall of the esophagus 
and stomach, small bowel, colon, pancreas, 
and liver. The terminal jejunum and the proximal 
ileum showed active and healing ulcers, related 
to vasculitic lesions (Figure 3). A small infarct 
was detected in the liver. The gallbladder showed 
Figure 2 – A – Large thrombotic embolus occluding the left superior lobar pulmonary artery; B – Microscopic 
view of the thrombus (H&E 12.5X).
Figure 3 – A – Healed areas in the mucosa of the ileum (arrows); B – Small artery in the submucosa with 
fibrinoid necrosis, occlusion and a granulomatous reaction with palisade of histiocytes, neutrophils and many 
eosinophils (H&E 400X).
Figure 4 – A - Necrotic crateriform ulcers in the gallbladder; B - Microscopic view of a necrotic ulcer with 
undermining borders and impregnation with bile on the top (H&E 12.5X).
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polyangiitis as an ANCA-associated vasculitis. 
EGPA is the least frequent vasculitis among this 
group of diseases and represents about 10% of all 
ANCA-related vasculitis.2,3
The natural course of EGPA has three 
sequential phases, not always distinct: (1) the 
prodromal phase: usually present during the second 
and third decades of life, lasts months to years and is 
characterized by atopy, namely: allergic rhinitis and 
asthma; (2) the eosinophilic phase: characterized 
by peripheral eosinophilia (> 10% of the differential 
count or over 1500 eosinophils/mm3) and organic 
eosinophilic tissue infiltration, especially the lungs 
and gastrointestinal tract; and (3) vasculitic phase: 
comprehends the systemic involvement by severe 
vasculitis affecting small- and medium-sized 
vessels associated with vascular and extravascular 
granulomatosis compromising the lungs, peripheral 
nerves, heart, and gastrointestinal tract. If untreated, 
the mortality rate reaches 50% of patients in the first 
3 months of disease.2,4
vasculitis, medium vessels thrombosis, and renal 
infarcts were present (Figure 5).
Microscopic vasculitis also affected the 
ovaries, adrenals, tongue, urinary bladder, and 
spleen. Vasculitis was not detected in the central 
nervous system (CNS) or in the heart.
DISCUSSION
The clinical features of this case report are 
compatible with the diagnosis of EGPA1, which is 
also called “allergic vasculitis” or “granulomatous 
angiitis.” It is an uncommon systemic necrotizing 
vasculitis involving small- and medium-sized vessels 
of many organs, namely: the lungs, peripheral 
nerves, heart, and gastrointestinal tract. The 
estimated annual incidence ranges between 0.11 
and 2.6 new cases per million, with a prevalence 
of 10.7-14 per million adults. The EGPA is sorted 
together with granulomatosis with angiitis (formerly 
called Wegener’s granulomatosis) and microscopic 
Figure 5 – A - Chronic vasculitis in a small kidney artery with luminal fibrosis (H&E 400X); B - Local thrombosis 
in a medium-sized kidney artery (H&E 100X); C - Glomerulosclerosis (H&E 400X); D - Cortical renal infarction 
related to arterial thrombosis (H&E 400X).
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gastrointestinal tract micro perforation appeared, 
but there was no need for surgical intervention. 
Probably a splanchnic vasculitis caused the gastric 
ischemia resulting in visceral wall necrosis and 
perforation. In the literature, there are several reports 
of single or multiple ulcers in the terminal ileum 
and colon, which progress to perforation requiring 
surgical treatment.6,7 The presence of ulceration 
on endoscopy is considered as a precursor lesion 
of perforation, and therefore particular attention 
should be given to the possibility of this severe 
complication. Corticosteroids increase the fibrotic 
changes within the vessel intima favoring vascular 
obstruction and consequently ischemia and further 
gastrointestinal perforation.6,-8 Digestive symptoms, 
including abdominal pain, bowel obstruction, nausea, 
vomiting, diarrhea, and bleeding are common and 
can occur in up to one-third of cases. Other findings 
include eosinophilic ascites, pancreatitis, acalculous 
cholecystitis, and eosinophilic infiltrate of the liver.8
Cardiac involvement is one of the most 
severe manifestations of EGPA and is responsible 
for approximately half of the deaths. The myocardial 
damage may be due to three factors: (1) coronary 
artery vasculitis; (2) myocardial injury caused by toxic 
mediators released by activated eosinophils; and 
(3) myocardial sclerosis or granulomas.2,3 Recent 
studies show that cardiac involvement may be 
present in 44-62% of cases.9,10 The manifestations 
are varied and include myocarditis, congestive heart 
failure, eosinophilic pericardial effusion, tamponade, 
valvular disease, and less often, coronary vasculitis. 
The occurrence of endomyocarditis may represent 
the most severe cardiac manifestation.9,10
Renal involvement occurs in approximately 
25% of cases of EGPA. Half of these cases 
manifest isolated proteinuria or microscopic 
hematuria and the other half present acute renal 
failure or rapidly progressive renal failure. The 
most common histological finding in these cases 
is the ANCA-associated necrotizing crescentic 
glomerulonephritis. Less frequently, other renal 
histological findings include eosinophilic interstitial 
nephritis, mesangial glomerulonephritis, and focal 
sclerosis.11
Among the laboratory workup of this case, 
the marked eosinophilia with 52% of the leukocytes 
accounting for 14,456 eosinophils/mm3 and the 
presence of ANCA were fundamental in supporting 
the diagnosis. These autoantibodies are found in 
40-60% of patients with EGPA, and just as in the 
present case, the perinuclear pattern is the one 
The patient of this report had a 5-year 
history of asthma and rhinitis adequately controlled 
without the need for corticosteroids The presence 
of asthma is the main clinical feature in EGPA and 
is present in over 95% of cases.2 Asthma precedes 
vasculitis for an average of 3-9 years; it usually 
begins in adulthood and tends to be more severe 
and refractory to treatment. Many cases require 
prolonged use of systemic corticosteroids, which 
is why there may be a partial or total suppression 
of the usual EGPA clinical signs. When the dose 
of corticosteroids is reduced the EGPA becomes 
evident. When the vasculitic phase ensues, asthma 
exacerbations usually increase in severity. Rarely, 
the symptoms of asthma improve in the vasculitic 
phase. The symptoms related to the involvement 
of the upper airways are found in 47-93% of the 
cases and include nasal polyps, allergic rhinitis, and 
chronic or recurrent sinusitis. Necrotizing lesions 
of the nasopharynx and upper airway are more 
common in granulomatosis with polyangiitis and are 
rare in the EGPA.2,5
Other pulmonary findings include 
opacities with eosinophilia, pleural effusion (often 
eosinophilic), nodules that seldom cavitate, and 
alveolar hemorrhage. These findings are reported 
in 50-70% of cases.2,5
In the case of this report, the presence 
of sensory and motor peripheral neuropathy 
with pain and motor deficits was confirmed 
by electromyography. In addition, the patient 
developed mental confusion, which improved after 
the prescription of corticosteroids, suggesting 
CNS involvement. The peripheral nervous system 
involvement occurs in up to 75% of cases and is 
one of the most important manifestations of the 
vasculitic phase.2,3 It usually starts as a mononeuritis 
multiplex (wrist or foot drop) and progress to 
symmetrical or asymmetrical polyneuropathy. 
Ischemic or hemorrhagic strokes and subarachnoid 
hemorrhage have also been reported but are rare 
and associated with poor prognosis and increased 
mortality.4
The skin lesions are very common in the 
vasculitic phase of EGPA. Palpable purpura, livedo 
reticularis, and subcutaneous nodules occur in up 
to 68% of cases.2,3 Nodules occur over the extensor 
surfaces of the lower and upper limbs—in the latter, 
it is particularly in the hands and elbows.
During the course of this case, abdominal 
complaints associated with tamponade 
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inflammatory activity and eosinophilia is observed.5 
Intravenous corticosteroids pulse therapy 
(methylprednisolone 1 g IV for 3 days) is reserved 
for patients with more severe manifestations. 
In patients with a poor-prognostic factor, oral or 
intravenous cyclophosphamide pulses should be 
associated with the corticosteroids for 6-12 months. 
Once the remission is induced, methotrexate, 
azathioprine, or mycophenolate mofetil should 
replace cyclophosphamide in order to maintain 
remission, reduce side effects, and promote the 
possibility of further gradual reduction of the 
corticosteroids doses. The use of cyclophosphamide 
has also been recommended in patients with severe 
peripheral neuropathy with the goal of reducing 
or preventing sequelae.17 In refractory cases, 
other therapeutic schemes may be used, such as 
plasmapheresis, intravenous immunoglobulin, anti-
tumor-necrosis-factor (TNF [infliximab, etanercept, 
and adalimumab]), rituximab, and mepolizumab.2,3,18
According to the above recommendations, 
the patient of this report may have received 
cyclophosphamide and corticosteroids because 
of severe peripheral neuropathy and the presence 
of at least two poor prognostic factors, namely: 
gastrointestinal disease (perforation) and CNS 
involvement (mental confusion).
Currently, most clinical series show a 5-year 
survival rate greater than 70%. Heart failure and/
or myocardial infarction, cerebral hemorrhage, 
renal failure, gastrointestinal bleeding, and status 
asthmaticus represent the most common causes 
of death. A large series of patients evaluated the 
survival according to the presence of poor-prognostic 
factors. After diagnosis, the 5-year mortality rate 
was 12% when none of these factors were present, 
26% in the presence of one factor, and 46% when 
three or more risk factors were present.16
In the case presented here, the cause of 
death was pulmonary thromboembolism. In the last 
decade, several studies highlight the occurrence 
of a significantly increased risk of thromboembolic 
disease in ANCA-related vasculitis19-21 and with 
eosinophilic syndrome (hypereosinophilia and 
EGPA).22,23 In these cases, there is a release of 
several cytokines TNF-α, interleukin-1 (IL-1) and 
interleukin-6 (IL-6), which activate the coagulation 
cascade favoring thrombosis. Thrombogenesis 
in EGPA is also related to eosinophilic tissue 
infiltration. The granules of eosinophils contain 
several proteins that are released when these 
cells are activated. Among these proteins are the 
associated with elevation of anti-myeloperoxidase 
(p-ANCA or MPO-ANCA).9,10 The presence of ANCA 
at the time of diagnosis is more often associated 
with renal involvement, peripheral neuropathy, and 
vasculitic lesions demonstrated on biopsies, while 
the negativity of the ANCA is more often associated 
with heart disease and fever.12
Akimoto et al.13 observed a tendency for 
patients positive for p-ANCA (anti-MPO antibody) to 
also be positive for other autoantibodies, such as 
anti-Sc1-70 antibody, anti-centromere antibody, anti-
microsome antibody, anti-thyroglobulin antibody and 
rheumatoid factor. Anti-centromere antibody occurs 
in a marked frequency in progressive systemic 
sclerosis specially the CREST syndrome and may 
also be found in primary biliary cirrhosis, Sjoegren’s 
syndrome, as well as in other autoimmune disorders, 
more rarely. The patient of this report exhibited a 
nuclear centromeric pattern at ANA testing, but 
did not show any clinical feature compatible with 
the above-cited diagnoses. We do not believe that 
the presence of this antibody, somehow, interfere 
with the established diagnosis of EGPA, but it is 
important to keep in mind that the presence of anti-
centromere may precede the CREST syndrome 
symptoms in years.14
The diagnostic criteria of the American 
College of Rheumatology (1990)15 for EGPA include 
the presence of asthma, peripheral eosinophilia (> 
10% or 1,500/mm3), mononeuropathy (including 
mononeuritis multiplex) or polyneuropathy, transient 
pulmonary infiltration on chest radiography, 
involvement of paranasal sinuses, and the presence 
of eosinophils in extravascular biopsy containing 
a blood vessel. The presence of four or more 
diagnostic criteria determines a sensitivity of 85% 
and a specificity of 99.7% for the EGPA diagnosis.
After the diagnostic process, a five-factor 
score of poor prognosis should be considered to 
determine the severity of the disease.16 These 
factors encompass cardiac, gastrointestinal disease 
(bleeding, perforation, infarction, or pancreatitis), 
renal failure (creatinine > 1.58 mg/dL), proteinuria 
(> 1 g/day), and CNS involvement.
Recent studies showed an easy remission 
induction with corticosteroids if no poor-prognostic 
factor is present.2,3 In these cases, the recommended 
initial dose is 1 mg/kg of prednisone (0.5-1.5 mg/kg) 
orally or equivalent for 6-12 weeks or until remission 
occurs with subsequent gradual dose tapering. 
When the disease is under control, a reduction of 
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tissue factor, eosinophilic cationic protein, and 
eosinophilic peroxidase, which have thrombotic 
effects. The mechanism by which eosinophils 
promote thrombosis includes platelet activation by 
tissue factor activation, blocking the anticoagulant 
activity of thrombomodulin by cationic proteins, and 
induction of tissue factor expression in endothelial 
cells by eosinophil peroxidase. In addition, 
eosinophils can synthesize and release the platelet 
activation factor (PAF), a potent mediator capable 
of inducing activation and platelet aggregation. 
Finally, eosinophils express CD40 ligand, involved 
in the initiation and progression of thrombosis by 
amplifying the inflammatory process.22,23
A recent review found 80 cases of thrombosis 
associated with EGPA.23 Venous thrombosis 
occurred in 57% of cases, arterial thrombosis in 
39%, and mixed thrombosis (arterial and venous) 
occurred in 4%. Frequently, these events are 
represented by deep vein thrombosis (34%) and 
occlusion of retinal vessels (23%). Pulmonary 
embolism occurred in 8% of cases.
CONCLUSION
Since patients with EGPA are at high risk of 
venous or arterial thrombosis and such events are 
more frequent during active disease, we emphasize 
the requirement of prophylaxis and/or treatment 
of thromboembolic complications in addition to 
immunosuppressive treatment.
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